Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Jul 21, 2026

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets.

GlobeNewsWire • Jul 16, 2026

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents.

GlobeNewsWire • Jul 13, 2026

3 Under-the-Radar Stocks to Buy and Hold

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.

The Motley Fool • Jul 10, 2026

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership.

PRNewsWire • Jul 2, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M.

GlobeNewsWire • Jun 3, 2026

Madrigal Pharmaceuticals Could Become The Next Vertex

Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label extensions potentially driving revenue to double-digit billions over the next decade. Competition from Novo Nordisk's Wegovy and upcoming Efruxifermin poses significant long-term risk, but MDGL enjoys a near-term lead and first-mover advantage.

Seeking Alpha • Jun 3, 2026

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

Growing body of clinical and real-world evidence supports the role of Rezdiffra ® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associated with cardiovascular risk , including LDL-C, ApoB and Lp(a), in a secondary analysis from the Phase 3 MAESTRO program In patients with well-compensated MASH cirrhosis (F4c), Rezdiffra improved a risk score – ANTICIPATE-NASH – that predicts the probability of experiencing severe liver-related events Multiple real-world analyses evaluating the use of Rezdiffra in routine clinical practice demonstrated early and sustained improvements in cardiometabolic parameters, liver-related biomarkers, and liver stiffness measurements; 49% of patients achieved ≥25% reduction in liver stiffness over a nine-month follow-up period CONSHOHOCKEN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced new analyses of Phase 3 data and real-world evidence demonstrating Rezdiffra reduced markers of cardiovascular and liver-related risk in patients with MASH.

GlobeNewsWire • May 27, 2026